Reprieve Cardiovascular

Reprieve Cardiovascular, Inc. is a clinical-stage medical technology company based in Milford, Massachusetts. The company focuses on developing innovative therapies for heart failure, particularly acute decompensated heart failure (ADHF). Reprieve Cardiovascular aims to improve the lives of over 25 million heart failure patients globally by offering personalized decongestion management solutions that enhance fluid removal, a key aspect of heart failure care. The core product, the Reprieve System, is an automated fluid management technology that provides real-time monitoring of physiological parameters, such as urine output. This system allows for personalized diuretic dosing and fluid replacement, giving healthcare providers better visibility and control during treatment. Reprieve Cardiovascular is conducting clinical trials, including the FASTR II pivotal global trial, to validate the safety and efficacy of its technology, supported by significant funding from investors. The company targets healthcare providers and hospitals, aiming to improve patient outcomes and reduce hospital readmissions through its advanced fluid management solutions.

• Employees 29
• Founded 2020
• Annual Revenue $3000000
• Total Funding $125000000